NCT00369499终止不适用
STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 656
- 试验地点
- 2
- 主要终点
- Mean values of the number of monthly migraine periods, with or without aura.
研究概览
简要总结
The primary objective of this Study is to compare the effect of transcatheter device closure of atrial shunting to a non-closure control group over a period from cessation of procedure related medication at 3 months until 9 months post randomization by determining the proportion of patients that experience a 50% or more reduction in the baseline monthly migraine attack frequency in each group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Migraine history of at least 1 year.
- •Migraine patients experiencing at least 2 migraine attacks per month.
- •Migraine patients experiencing at least 1 migraine attack with aura per month.
- •Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials. At least one of the classes shall come from beta-blockers, anticonvulsants, calcium channel blockers and tricyclic antidepressants.
- •Aged 18 - 50 years and of legal age in the host country.
- •The patient or legal guardian has signed a study specific informed consent form agreeing to data collection and follow-up requirements.
- •The patient agrees to abstain from starting prophylactic migraine medication or agrees to maintain existing prophylactic migraine medication without changing dose or drug from entering the baseline period throughout the duration of the study until final assessments.
- •Documented right to left shunt that is suitable for device closure.
排除标准
- •Taking migraine preventative medication for conditions other than migraine.
- •History of 15 or more headache days per month.
- •8 or more non-migraine headache days per month.
- •Overuse of acute headache medication (use on 10 or more days per month).
- •Patient has severe central nervous system disease such as seizure disorder, inflammatory disease of the central nervous system, or a previous stroke.
- •Previous surgical or device closure of a PFO or ASD.
- •Artificial heart valve.
- •Pacemaker or ICD implanted within past 3 months.
- •Anatomic variant that could affect successful deployment such as coronary sinus, pulmonary veins, Chiari network.
- •Uncontrolled bacteremias or dental or surgical procedure within past 30 days or planned within study period.
- •Allergy to contrast media, and/or to any component of the device to be used.
- •Contraindicated for any medication used during or after the procedure.
- •History of atrial fibrillation or atrial flutter (chronic or paroxysmal).
- •Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.
- •Patient is undergoing dialysis for renal failure.
- •Patient has NYHA class 3 or 4 cardiac failure.
- •Patient is pregnant, or intends to become pregnant during the trial period.
- •Patient requires anticoagulation therapy for a concomitant condition.
结局指标
主要结局
Mean values of the number of monthly migraine periods, with or without aura.
次要结局
- Mean values of monthly migraine frequency with or without aura.
- Quality of life using a Headache Impact Test Questionnaire.
研究者
研究点 (2)
Loading locations...
相似试验
终止
3 期
ESCAPE Migraine TrialMigraine DisordersHeart Septal Defects, AtrialNCT00267371Abbott Medical Devices168
暂停
不适用
STOP PAIPFO, migraine, closureForamen ovale persistens, migraine, sluitingNL-OMON22085St Jude Medical incThe corporate village 11- box F1B-1935 ZaventemBelgium0032 27746937Coordinating clinical investigators: Prof MD Ferrari, Neurology department LUMC50
终止
不适用
The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCIPFOStrokeTIAPatent Foramen OvaleNCT01018355Hillerod Hospital, Denmark3,000
招募中
3 期
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 YearsCryptogenic Ischemic StrokePatent Foramen OvaleNCT05387954Assistance Publique - Hôpitaux de Paris792
已完成
不适用
Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal DefectsVentricular Septal DefectsNCT00890799Xijing Hospital200